瑞舒伐他汀对慢性心力衰竭患者血浆白细胞介素18的影响

目的：探讨瑞舒伐他汀对慢性心力衰竭患者血浆白细胞介素18（IL-18）的影响。方法选取2013年接诊的48例心脏衰竭（纽约心脏病协会NYHA分级Ⅱ～Ⅲ级）患者，根据随机数字法均分为常规治疗组和干预组（n=24），其中常规治疗组给予强心、利尿、扩血管治疗，干预组在此基础上加用瑞舒伐他汀10 mg/晚，治疗16周。另选取本院体检健康同龄人30例作为健康对照组，所有研究对象均测定左心室射血分数（LVEF）、B型钠尿肽前体（proBNP）和白细胞介素-18（IL-18）。结果（1）LVEF：相比于常规治疗组（62.80±0.15）%，健康对照组（83.36±2.66）%及干预组（88.63±2.04）%，显著偏高，差异有统计学意义（P〈0.01）；proBNP：相比于健康对照组〈60 ng/L，常规治疗组（1556.3±356.4）ng/L及干预组（453.2±158.1）ng/L显著较高，差异有统计学意义（P〈0.01）。（2）IL-18含量：常规治疗组（1.4803±0.0806）mmol/L及干预组（0.6045±0.0214）mmol/L显著高于健康对照组（0.3486±0.0482）mmol/L（P〈0.05），而且常规治疗组显著高于干预组，差异有统计学意义（P〈0.01）。结论瑞舒伐他汀显著降低慢性心力衰竭患者血浆白细胞介素18水平，改善心脏功能，有益于慢性心力衰竭的治疗。

Objective To investigate the effects of rosuvastatin on plasma interleukin-18 （IL-18） of patients with chronic heart failure.Methods 48 cases of heart failure （NYHA gradeⅡ-Ⅲ） patients selected and diagnosed from the year 2013 were randomly divided into two groups： 24 cases of conventional therapy group in which they were given cardiac, diuretic and expanding endovascular treatment, and 24 cases of intervention group in which they were given rosuvastatin 10mg per night for 16 weeks besides the conventional therapy. Furthermore, 30 cases of medically healthy peers were selected as the healthy control group, in which all subjects were measured left ventricular ejection fraction （LVEF）, B-type natriuretic peptide precursor （proBNP） and IL-18.Results （1） LVEF： compared with that of the conventional therapy group（62.80±0.15）%, LVEF of the healthy control group （83.36±2.66）% and intervention group （88.63±2.04）%,was significantly higher, and the difference was statistically significant （P〈0.01）; proBNP： compared with that of the healthy control group 〈60ng/L, proBNP of the conventional therapy group （1556.3±356.4）ng/L and intervention group（453.2 ±158.1）ng/L was significantly higher, and the difference was statistically significant （P〈0.01）. （2） IL-18 content of the conventional therapy group and the intervention group was significantly higher than the healthy control group （0.3486±0.0482）mmol/L （P〈0.01）, and that of the conventional treatment group （1.4803±0.0806）mmol/L was significantly higher than in the intervention group （0.6045±0.0214）mmol/L, and the difference was statistically significant （P〈0.05）.Conclusion Rosuvastatin can significantly reduce IL-18 levels of patients with chronic heart failure, improves heart function, and benefits the treatment of chronic heart failure.